Blog
    Regulatory UpdateFor PhysiciansJuly 30, 2026

    FDA Bulk Substance Status and Peptide Safety Signals

    Review FDA Category 2 classifications for BPC-157 and TB-500, 503A eligibility shifts, and postmarketing safety signals for GLP-1 receptor agonists.

    Clinical Question

    How does the current FDA regulatory landscape and postmarketing safety data influence the clinical evaluation of commonly utilized peptides, and what specific safety signals have emerged for approved and investigational therapies?

    Evidence Snapshot

    • Regulatory Status: Multiple peptides including BPC-157, TB-500, and several growth hormone secretagogues are classified as Category 2 bulk substances as of March 2026.
    • 503A/B Eligibility: Several peptides (AOD-9604, Ipamorelin, Selank, CJC-1295) saw nominations withdrawn or were removed from consideration in September 2024.
    • Safety Signals: FAERS data for Semaglutide indicates strong signals for gastrointestinal events, with emerging monitoring for NAION and pulmonary aspiration.
    • Clinical Outcomes: Phase III data confirms 14.9% to 22.5% weight loss for approved GLP-1/GIP receptor agonists, while Thymosin Alpha-1 failed to demonstrate mortality reduction in Phase III sepsis trials.

    What the Research Shows

    The regulatory landscape for compounded peptides has undergone significant revision. As of March 2026, the FDA has categorized BPC-157, TB-500, and GHK-Cu under Category 2 bulk substances. This classification is primarily driven by significant safety risks, including immunogenicity and a lack of human safety data. BPC-157 and TB-500 are currently ineligible for routine compounding, with BPC-157 specifically noted for a lack of safety data and immunogenicity concerns.

    Regulatory shifts occurred in September 2024 for several compounds. AOD-9604, Ipamorelin, and Selank had their nominations withdrawn from 503A consideration. CJC-1295 was removed following safety concerns identified by the FDA, such as increased heart rate. Thymosin Alpha-1, while approved in over 35 countries as Zadaxin, remains non-FDA approved and was removed from the 503A Category 2 list in September 2024 pending advisory review, though it remains a substance of concern under interim policy.

    In clinical trials, Semaglutide (STEP 1) achieved 14.9% weight loss, and the SELECT trial demonstrated a 20% reduction in Major Adverse Cardiovascular Events (MACE). Tirzepatide demonstrated 22.5% weight loss in the SURMOUNT-1 trial and was found superior to semaglutide in the SURMOUNT-5 trial. Retatrutide Phase II data showed 24.2% weight loss at a 12mg dose, with Phase III (TRIUMPH-3) ongoing. Conversely, Thymosin Alpha-1 Phase III data (NCT02867267) for sepsis was negative, showing no reduction in mortality.

    Safety signals from the FAERS database for Semaglutide include strong, dose-dependent signals for nausea and vomiting (187,757 total GLP-1 RA reports through 2023). Emerging signals include Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), with 96 cases reported through December 2024, currently under EMA review. Intestinal obstruction and pulmonary aspiration have also been added to labeling based on postmarketing data.

    Mechanism

    Mechanistic data is limited to specific identified risks in the regulatory records. The FDA identifies immunogenicity as a primary risk factor for GHK-Cu, GHRP-2, TB-500, and BPC-157. For CJC-1295, the identified physiological mechanism involves an increase in heart rate. For Semaglutide, delayed gastric emptying is a documented mechanism contributing to both therapeutic impact and potential complications, such as impaired oral medication absorption and increased risk of pulmonary aspiration during general anesthesia.

    Limitations of the Evidence

    There is a profound lack of human exposure and safety data for several peptides currently classified in Category 2, including TB-500 and BPC-157. While compounds like Selank and Semax are approved in Russia, they lack FDA approval, limiting standardized safety oversight in the United States. Safety signals for NAION and suicidal ideation are currently under evaluation or review, and current data do not yet support a definitive higher risk for suicidal ideation compared to background rates. Additionally, several clinical trials, such as the STAY trial for Tesamorelin and TRIUMPH-3 for Retatrutide, are ongoing, meaning long-term outcomes remain undetermined.

    Clinical Takeaway

    Clinicians should balance the demonstrated efficacy of approved agents like Semaglutide and Tirzepatide against emerging safety signals regarding NAION and aspiration risks. The regulatory status of compounded peptides like BPC-157 and Thymosin Alpha-1 remains restrictive due to FDA concerns regarding immunogenicity and lack of clinical safety data. The transition of several peptides to Category 2 or the withdrawal of their nominations indicates a heightened regulatory scrutiny of bulk substances used in compounding.

    Sources

    • FDA Regulatory Status Records (BPC-157, Thymosin Alpha-1, TB-500, AOD-9604, CJC-1295, Ipamorelin, Selank, Semax, GHK-Cu, GHRP-2)
    • FAERS Safety Signal Data (Semaglutide; ROR/PRR reports through 2024)
    • Clinical Trial Records (NCT03548935, NCT03574597, NCT04184622, NCT05024032, NCT04881706, NCT00451282, NCT02867267)

    This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

    Referenced Peptides

    bpc 157semaglutidethymosin alpha 1tirzepatidetb 500

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.